XIAP and cIAP are the most prominent and potent members of this family and its pharmacologic blockade with SMAC mimetics has been shown in a number of experimental settings [39, 40] but also as a means to sensitize ovarian cancer efficiently to chemotherapy [25–29, 41], including in a clinical setting [42]. The gene discussed is XIAP; the disease is ovarian carcinoma.